Skip to main content
. 2015 Jan 6;54(2):133–146. doi: 10.1007/s40262-014-0224-4

Fig. 6.

Fig. 6

Dose-dependent effects of mipomersen as a single agent on (a) apoB and (b) LDL cholesterol in patients with mild to moderate hyperlipidemia. Patients (N = 50) were treated for 13 weeks with mipomersen at a dose of 50–400 mg, or placebo [34]. Data presented are the median percentage change from baseline from day 1 to day 175. apoB apolipoprotein B, LDL low-density lipoprotein